Drugs / Magnesium citrate, tribasic anhydrous
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02822222 | Jun → Jul 2016 | essential hypertension | RMJ Holdings, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium citrate, tribasic anhydrous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822222 ↗ |